Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Pharma
Tremfya enters crowded ulcerative colitis arena with FDA nod
Tremfya enters the space as J&J’s Stelara, which is approved for both forms of IBD, nears biosimilar competition and IRA-related price concessions.
Zoey Becker
Sep 11, 2024 6:58pm
AbbVie-FutureGen, Takeda, Kyowa Kirin—Fierce Pharma Asia
Jun 14, 2024 5:00am
UPDATED: J&J readies Tremfya for IBD showdown with AbbVie, Lilly
May 21, 2024 9:49am
Celltrion signs 'The Traitors' star for bowel disease campaign
May 20, 2024 10:10am
Delayed FDA nod moves Lilly into crowded ulcerative colitis field
Oct 27, 2023 11:10am
AbbVie trumpets Skyrizi's resounding win against J&J's Stelara
Oct 16, 2023 10:07am
